Status:
COMPLETED
Association Between Age-related Macular Degeneration and Cognitive Impairment Based on Exosome Proteomics
Lead Sponsor:
Shanghai 10th People's Hospital
Conditions:
Age Related Macular Degeneration
Mild Cognitive Impairment (MCI)
Eligibility:
All Genders
40-100 years
Brief Summary
Aim: Preliminary serum exosomal proteomics of patients with dry age-related macular degeneration (AMD) and mild cognitive impairment (MCI) were analyzed using proteomics technology. Methods: Peripher...
Eligibility Criteria
Inclusion
- All dry AMD patients were diagnosed based on the Clinical Classification of Age-Related Macular Degeneration issued by the American Academy of Ophthalmology.
- All patients with MCI meet the Petersen criteria, including memory impairment, no abnormal cognitive function, dementia, or some cognitive impairment in daily life. A Mini-Mental State Examination (MMSE) score ≥24 points and a Montreal Cognitive Assessment (MoCA) score between 18 and 25 points were required.
Exclusion
- The systemic physical exclusion criteria were as follows:(a) Metabolic syndromes such as diabetes or obesity;(b) Uncontrolled hypertension or hypotension;(c) Serious cardiac disease;(d) Neurological diseases, including Parkinson's disease, multiple sclerosis, or peripheral neuropathy;(e) Psychiatric diseases such as hallucinations or depressive disorders;(f) a history of brain injury, stroke, or substance abuse.
- The ocular exclusion criteria were as follows: (a) intraocular pressure(IOP) \> 21 mmHg; (b) axial length(AL) \> 25 mm or \<22 mm; (c) anterior segment disease affecting fundus examination; (d) retinal pathologic changes associated with high myopia or serious refractive errors (\>5D of spherical equivalent refraction or \>3D of astigmatism); (e) concomitant ocular diseases, such as glaucoma or retinal detachment; (f) other genetic ocular diseases; and (g) other fundus diseases, including macular hiatus, macular edema, retinal vascular occlusion, or central serous chorioretinopathy.
Key Trial Info
Start Date :
April 1 2019
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
June 3 2024
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT06883461
Start Date
April 1 2019
End Date
June 3 2024
Last Update
March 19 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Shanghai Tenth People's Hospital
Shanghai, Shanghai Municipality, China, 200070